rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ALGS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Aligos earnings beat by $0.10, revenue topped estimates
      Nov 6Investing.comALGS
      Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results

      SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the third quarter 2026. “This past quarter we continued to advance our Phase 2 B-SUPREME study of pevifoscorvir sodium, which remains on track for the topline data readout in late

      Nov 6Yahoo FinanceALGS
      Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2026
      Nov 5Yahoo FinanceALGS
      H.C. Wainwright Sticks to Their Buy Rating for Aligos Therapeutics (ALGS)

      Detailed price information for Aligos Therapeutics Inc (ALGS-Q) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailALGS
      Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026

      SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced five abstracts have been accepted for presentation at the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting® 2026, being held November 5 – 9, 2026 in Denver, CO. The abstracts released today can be found on

      Oct 5Yahoo FinanceALGS
      Aligos Therapeutics Amends Long-Term Headquarters Lease Agreement

      Detailed price information for Aligos Therapeutics Inc (ALGS-Q) from The Globe and Mail including charting and trades.

      Sep 16The Globe and MailALGS
      Aligos Therapeutics at Cantor Fitzgerald conference: hbv pipeline in focus
      Sep 10Investing.comALGS
      Aligos Therapeutics to Present at the Cantor Global Healthcare Conference

      SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the Cantor Global Healthcare Conference. Cantor Global Healthcare Conference Fireside Chat on Wednesday, September 9, 2026 at 8:00am ET The presentation will premiere at the time listed above

      Sep 2Yahoo FinanceALGS
      Aligos Therapeutics Shares Rise 7.6% Premarket Following Recent Company Updates

      Aligos Therapeutics (NASDAQ:ALGS) shares rose 7. 6% to $6.

      Sep 2Yahoo FinanceALGS
      Why is Aligos Therapeutics stock rallying 7% today?
      Sep 2Investing.comALGS

      This is the newest page. Registered accounts read further back.